Abnova Taiwan Corp Market Cap ($37.87 Million)
Market Cap & Net Worth: Abnova Taiwan Corp (4133)
Abnova Taiwan Corp market cap. Abnova Taiwan Corp (TW:4133) has a market capitalization of $37.87 Million (NT$1.20 Billion) as of November 5, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #22711 globally and #1424 in its home market, demonstrating a -4.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abnova Taiwan Corp's stock price NT$19.85 by its total outstanding shares 60554000 (60.55 Million). Also see 4133 cash flow metrics for how efficiently the company converts equity into cash flow.
Abnova Taiwan Corp Market Cap History (2015–2026)
Abnova Taiwan Corp market cap history from 2015 to 2026. Data shows change from $57.76 Million to $37.87 Million (-3.20% CAGR). Check 4133 stock price for real-time trading data and today's change.
Abnova Taiwan Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abnova Taiwan Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Abnova Taiwan Corp equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.12x
Abnova Taiwan Corp's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $64.91 Million | $439.83 Million | $53.54 Million | 0.15x | 1.21x |
| 2017 | $70.20 Million | $475.07 Million | $58.97 Million | 0.15x | 1.19x |
| 2018 | $54.76 Million | $426.02 Million | $46.12 Million | 0.13x | 1.19x |
| 2019 | $47.36 Million | $414.16 Million | $3.26 Million | 0.11x | 14.51x |
| 2020 | $108.61 Million | $456.45 Million | $36.53 Million | 0.24x | 2.97x |
| 2021 | $82.15 Million | $451.49 Million | $28.37 Million | 0.18x | 2.90x |
| 2022 | $78.60 Million | $411.76 Million | $74.84 Million | 0.19x | 1.05x |
| 2023 | $66.96 Million | $382.05 Million | $43.68 Million | 0.18x | 1.53x |
| 2024 | $56.57 Million | $355.26 Million | $61.61 Million | 0.16x | 0.92x |
| 2025 | $43.31 Million | $351.30 Million | -$1.14 Million | 0.12x | N/A |
Competitor Companies of 4133 by Market Capitalization
Companies near Abnova Taiwan Corp in the global market cap rankings as of November 5, 2026. Also see 4133 total asset value for a full breakdown of the balance sheet.
Key companies related to Abnova Taiwan Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Abnova Taiwan Corp (2015–2026)
Market capitalization of Abnova Taiwan Corp from 2015 to today. Between 2015 and today, Abnova Taiwan Corp's market cap moved from $57.76 Million to $ 37.87 Million, with a yearly change of -3.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$37.87 Million | -12.56% |
| 2025 | NT$43.31 Million | -23.44% |
| 2024 | NT$56.57 Million | -15.53% |
| 2023 | NT$66.96 Million | -14.81% |
| 2022 | NT$78.60 Million | -4.33% |
| 2021 | NT$82.15 Million | -24.36% |
| 2020 | NT$108.61 Million | +129.34% |
| 2019 | NT$47.36 Million | -13.51% |
| 2018 | NT$54.76 Million | -22.00% |
| 2017 | NT$70.20 Million | +8.15% |
| 2016 | NT$64.91 Million | +12.38% |
| 2015 | NT$57.76 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Abnova Taiwan Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.87 Million USD |
| MoneyControl | $37.87 Million USD |
| MarketWatch | $37.87 Million USD |
| marketcap.company | $37.87 Million USD |
| Reuters | $37.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more